a2 Milk Company recalls infant formula due to possible health risk

Webp martymakary
Dr. Marty Makary, Commissioner of Food and Drugs | McDermott, Will & Emery

a2 Milk Company recalls infant formula due to possible health risk

ORGANIZATIONS IN THIS STORY

The a2 Milk Company announced on May 2 that it has voluntarily recalled three batches of its imported a2 Platinum Premium USA label infant formula for ages 0-12 months because of the presence of cereulide, a toxin. The product is sold only in the United States.

Cereulide is produced by some strains of Bacillus cereus bacteria and cannot be eliminated by preparing formula with hot water. Symptoms from exposure typically develop within thirty minutes to six hours after ingestion and usually include nausea and vomiting, which generally resolve within twenty-four hours. Infants are at higher risk due to their developing immune systems and may experience complications such as dehydration that require medical care.

The affected product comes in 31.7-ounce tins with batch numbers 2210269454 (use by July 15, 2026), 2210324609 (use by January 21, 2027), and 2210321712 (use by January 15, 2027). The batch number and expiration date can be found on the bottom of each tin. Distribution was national through the company’s website, Amazon, and Meijer stores as part of Operation Fly Formula. Importation rights expired December 31, 2025; the product was discontinued before this recall began. Of the total three batches—63,078 units—an estimated 16,428 were sold to consumers.

No confirmed illnesses or harm have been reported so far; however, consumers are advised not to use any affected products. The recall followed additional testing prompted by new guidance from New Zealand's food regulatory authority that detected cereulide in an ingredient used in these batches.

This action is being taken with knowledge of the U.S. Food and Drug Administration. Consumers who purchased these products should stop using them immediately and either dispose of them or return them for a refund at their place of purchase. Anyone whose infant shows symptoms should contact their healthcare provider right away or report incidents directly to the FDA via SmartHub or MedWatch.

ORGANIZATIONS IN THIS STORY